Yifan Pharmaceutical
Pharmaceutical R&D focused on biologics and small molecules.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (18 %) | (13 %) | 6 % | 27 % | 24 % | 12 % | 16 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 13 % | 16 % | 11 % | 18 % | 17 % | 19 % | 18 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 6 % | 5 % | (14 %) | 7 % | 11 % | 13 % | 13 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 5 % | 8 % | 6 % | - | - | - |
Source: Company filings or news article, Equity research estimates
The story of Yifan Pharmaceutical begins in 1994, establishing itself as a key pharmaceutical company in China. The company, led by Chairman and General Manager Mr. Xian Feng Cheng, focused on producing a range of medicines, from traditional Chinese remedies to drugs for gynecology, pediatrics, and dermatology. Its core business also included active pharmaceutical ingredients (APIs), like Vitamin B5, which it successfully sold to international markets, including Europe and the United States. A significant turning point for the company came in 2014 when it was listed on the main board of the Shenzhen Stock Exchange. This event provided the capital and platform for greater ambition. Shortly after, in October 2016, the company officially changed its name from Yifan Xinfu Pharmaceutical Co., Ltd. to Yifan Pharmaceutical Co., Ltd. This period marked a strategic shift towards innovation and global reach. Demonstrating its new strategy, Yifan acquired a majority stake in Generon Corporation, a Shanghai-based biologics research and development firm, in 2016. This move significantly bolstered its pipeline with innovative biologic drugs targeting areas like chemotherapy-induced neutropenia. Today, Yifan Pharmaceutical operates with a global footprint, featuring research centers in the U.S. and China and a business network spanning nearly 40 countries. The company continues to develop a diverse portfolio across biologics, small molecules, and traditional Chinese medicines, aiming to address unmet medical needs worldwide.
